What Makes a Pharmaceutical ERP System Different?

Why this matters

IFS notes that batch traceability from active ingredient to finished good is mandatory under cGMP. From 2026, DSCSA serialisation enforcement adds further obligations in US supply chains. A retrofitted compliance module frequently fails an EMA audit, because data integrity is interrupted at multiple points.

A real-world example

A generics manufacturer in Hesse with 540 employees replaced its grown ERP after an EMA inspection documented batch-traceability gaps. The new system was implemented under validation from day one; remediation costs would otherwise have exceeded the entire original implementation budget.

Related terms: pharma and life sciences consulting, ERP in a validated EU pharma environment, supply-chain-first pharma ERP.

What pharma ERP must cover non-negotiably

Thinking from first principles, compliance is not a feature; it is the structure of the data model. Bolt-on compliance creates two audit problems: the gap itself and the impression of weak process discipline.

• Recipe and bill-of-material management with versioning and an approval workflow.
• Batch tracking from active substance to finished good with bidirectional traceability.
• Electronic signatures per FDA 21 CFR Part 11 or EU Annex 11 chapter 7.
• Field-level audit trail, tamper-evident and searchable.
• Multi-stage quality release with role separation between production and QA.

Active-ingredient versus finished-dose: what you must distinguish

Active-ingredient producers and finished-dose manufacturers have structurally different ERP needs: API producers work batch- and campaign-oriented; finished-dose manufacturers work lot-based. An ERP that only supports one creates audit-visible workarounds in the other.

Read next: ERP system fundamentals.

Next step

To assess whether your ERP candidate structurally supports EMA requirements, book a pharma-selection scoping call.